A novel GIP analogue, ZP 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents

• Published in: Diabetes, obesity & metabolism Vol. 20; no. 1; pp. 60 - 68
• Main Authors: Nørregaard, Pia K., Deryabina, Maria A., Tofteng Shelton, Pernille, Fog, Jacob U., Daugaard, Jens R., Eriksson, Per‐Olof, Larsen, Lone F., Jessen, Lene
• Format: Journal Article
• Language: English
• Published: 01.01.2018
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.13034

Aim To investigate the effects of the novel glucose‐dependent insulinotropic polypeptide ( GIP ) analogue, ZP 4165, on body weight and glycaemic control in rodents, and to investigate if ZP 4165 modulates the anti‐obesity and anti‐hyperglycaemic effects of a glucagon‐like peptide‐1 ( GLP ‐1) agonist (liraglutide). Methods The acute insulinotropic effect of ZP 4165 was investigated in rats during an oral glucose tolerance test. The long‐term effects of ZP 4165 on body weight and glycaemic control, either alone or in combination with liraglutide, were assessed in diet‐induced obese mice and diabetic db/db mice. Results ZP 4165 showed insulinotropic action in rats. The GIP analogue did not alter the body weight of obese mice but enhanced GLP ‐1‐induced weight loss. In diabetic mice, 4 weeks’ dosing with ZP 4165 reduced glycated haemoglobin levels vs vehicle by an extent similar to the GLP ‐1 agonist. Conclusions ZP 4165 potentiated the anti‐obesity effect of a GLP ‐1 agonist in obese mice and improved glycaemic control in diabetic mice. These studies support further investigation of dual‐incretin therapy as a more effective treatment option than mono GLP ‐1 medication for type 2 diabetes mellitus and obesity.